MATINAS BIOPHARMA
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing therapeutics for the treatment of fungal and bacterial infections. The company develops orally delivered therapeutics based on a proprietary, lipid crystal drug delivery platform called cochleate delivery technology. Its lead product candidate is MAT 2203, an oral formulation of the broad spectrum anti-fungal drug amphotericin B that is in Phase II study for the treatment of fungal... infections. The company is also involved in developing MAT2501, an orally-administered, encochleated formulation of amikacin for acute bacterial infections, including non-tuberculous mycobacterium (NTM) and multi-drug resistant gram negative bacterial infections. In addition, it is exploring development and partnership options for MAT9001, a prescription-only omega-3 fatty acid-based composition under development for hypertriglyceridemia; and MAT8800 discovery program, which intends to identify product candidates derived from omega-3 fatty acids for the treatment of non-alcoholic fatty liver disease. Matinas BioPharma Holdings, Inc. was incorporated in 2013 and is based in Bedminster, New Jersey.
MATINAS BIOPHARMA
Industry:
Biopharma Biotechnology Therapeutics
Founded:
2011-01-01
Address:
Tarpon Springs, Florida, United States
Country:
United States
Website Url:
http://www.matinasbiopharma.com
Total Employee:
11+
Status:
Active
Contact:
1(908) 443-1860
Email Addresses:
[email protected]
Total Funding:
58.74 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager Content Delivery Network
Similar Organizations
Chiasma
Chiasma is a biopharmaceutical company developing oral drugs for the treatment of orphan diseases.
Proteostasis Therapeutics
Proteostasis Therapeutics is a clinical stage biopharmaceutical company developing small molecule therapeutics to treat cystic fibrosis.
Spero Therapeutics
Spero Therapeutics develops therapeutics for treatment of gram-negative infections.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2015-01-30 | Aquarius Biotechnologies | Aquarius Biotechnologies acquired by MATINAS BIOPHARMA | N/A |
Investors List
SternAegis
SternAegis investment in Venture Round - MATINAS BIOPHARMA
Key Employee Changes
Official Site Inspections
http://www.matinasbiopharma.com
- Host name: ec2-174-129-30-187.compute-1.amazonaws.com
- IP address: 174.129.30.187
- Location: Ashburn United States
- Latitude: 39.0481
- Longitude: -77.4728
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20149
More informations about "MATINAS BIOPHARMA"
Matinas BioPharma Holdings, Inc. (MTNB)
Jun 24, 2024 · Improving the intracellular delivery of important therapeutics. Our LNC platform enables safe, intracellular, oral- delivery of small molecules and small oligonucleotides.See details»
About Us :: Matinas BioPharma Holdings, Inc. (MTNB)
Matinas is an emerging clinical-stage biopharmaceutical company, based in Bedminster, New Jersey. Since commencing operations in 2013, we have been working to develop novel, life-changing pharmaceutical products. What …See details»
Company Information :: Matinas BioPharma Holdings, …
Matinas is an emerging clinical-stage biopharmaceutical company, based in Bedminster, New Jersey. Since commencing operations in 2013, we have been working to develop novel, life-changing pharmaceutical products. What …See details»
MATINAS BIOPHARMA - Crunchbase Company Profile …
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing therapeutics for the treatment of fungal and bacterial infections. The company develops orally delivered therapeutics …See details»
Matinas BioPharma - LinkedIn
Matinas BioPharma (NYSE AMER: MTNB) is a biopharmaceutical company focused on improving the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform...See details»
Company Description - Stock Analysis
6 days ago · Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform …See details»
Matinas Biopharma, Inc. Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Matinas Biopharma, Inc. of Bedminster, NJ. Get the latest business insights from Dun & Bradstreet.See details»
BioNTech and Matinas BioPharma Announce Exclusive Research ...
Apr 11, 2022 · MAINZ, Germany and BEDMINSTER, New Jersey (USA), April 11, 2022 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Matinas BioPharma (NYSE AMER: MTNB, …See details»
Matinas BioPharma Holdings - Overview, News & Similar
Apr 2, 2024 · Matinas BioPharma Holdings contact info: Phone number: (908) 484-8805 Website: www.matinasbiopharma.com What does Matinas BioPharma Holdings do? Matinas …See details»
Investor Relations :: Matinas BioPharma Holdings, Inc. (MTNB)
Jun 24, 2024 · Matinas is an emerging clinical-stage biopharmaceutical company, based in Bedminster, New Jersey. Since commencing operations in 2013, we have been working to …See details»
MATINAS BIOPHARMA - VentureRadar
Website: http://www.matinasbiopharma.com/ Develops lipid-crystal nano-particle cochleate technology to encapsulate drugs, improving safety, tolerability, and oral bioavailability, with …See details»
Matinas BioPharma Holdings, Inc. (MTNB) - Stock Analysis
2 days ago · Get a real-time Matinas BioPharma Holdings, Inc. (MTNB) stock price quote with breaking news, financials, statistics, charts and more.See details»
Matinas BioPharma Provides Update to MAT2203 Regulatory and …
BEDMINSTER, N.J., Dec. 21, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering …See details»
Matinas BioPharma Announces Collaboration with National …
Jan 12, 2023 · Matinas BioPharma is a biopharmaceutical company focused on improving the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) …See details»
Matinas BioPharma Successfully Reaches Agreement with FDA for …
BEDMINSTER, N.J., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering …See details»
New In Vitro Data Showing Matinas BioPharma’s LNC Platform …
May 16, 2024 · The combination of its unique mechanism of action and flexibility with routes of administration (including oral) positions Matinas’ LNC technology to potentially become a …See details»
Matinas BioPharma Demonstrates in vivo Biological Activity
Dec 27, 2023 · Matinas BioPharma is a biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology.See details»
Matinas BioPharma - Facebook
Matinas BioPharma. 14,323 likes · 61 talking about this. Matinas BioPharma (NYSE AMER: MTNB) is a biopharmaceutical focused on improving the...See details»
News :: Matinas BioPharma Holdings, Inc. (MTNB)
Aug 7, 2024 · Matinas in the news. Biotech 2012 Innovation Corridor - Our technology was featured at the Biotech 2012 Innovation Corridor for the demonstrated ability to orally deliver …See details»
BioNTech and Matinas BioPharma Announce Exclusive Research ...
Apr 11, 2022 · Matinas BioPharma is a biopharmaceutical company focused on redefining the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) …See details»